BPAN — Beta-Propeller Protein-Associated Neurodegeneration

BPAN — Beta-Propeller Protein-Associated Neurodegeneration

Overview

BPAN (Beta-Propeller Protein-Associated Neurodegeneration) is the most common X-linked NBIA disorder, caused by de novo mutations in the WDR45 gene (WD40 Repeat Protein 45) on chromosome Xp13. BPAN is unique among NBIA subtypes because the primary defect involves autophagy-lysosomal trafficking rather than iron metabolism itself — iron accumulation is a secondary consequence of autophagic failure. The disorder follows a characteristic biphasic pattern: early-onset seizures and developmental delay in childhood, followed by progressive neurodegeneration in adulthood[1].

Genetics and Inheritance

| Feature | Detail |
|---------|--------|
| Gene | WDR45 (WD40 Repeat Protein 45) on Xp13 |
| Inheritance | X-linked dominant (de novo mutations in most cases) |
| Mechanism | Predominantly loss-of-function (nonsense/frameshift) |
| Allelic disorder | WARIXX (WARS2-related neurodevelopmental disorder) |
| Protein | WDR45/WIPI4 (autophagy-related beta-propeller protein) |

WDR45 encodes WIPI4, a key component of the autophagy initiation machinery. It contains six WD40 repeats forming a beta-propeller structure that mediates protein-protein interactions essential for autophagosome formation. The protein binds to the PI3KC3 (PI3-kinase class 3) complex and regulates the conversion of omegasomes into autophagosomes.

Molecular Mechanism

```mermaid
flowchart TD
A["WDR45 De Novo Mutation"] --> B["Loss of WIPI4 Function"]

BPAN — Beta-Propeller Protein-Associated Neurodegeneration

Overview

BPAN (Beta-Propeller Protein-Associated Neurodegeneration) is the most common X-linked NBIA disorder, caused by de novo mutations in the WDR45 gene (WD40 Repeat Protein 45) on chromosome Xp13. BPAN is unique among NBIA subtypes because the primary defect involves autophagy-lysosomal trafficking rather than iron metabolism itself — iron accumulation is a secondary consequence of autophagic failure. The disorder follows a characteristic biphasic pattern: early-onset seizures and developmental delay in childhood, followed by progressive neurodegeneration in adulthood[1].

Genetics and Inheritance

| Feature | Detail |
|---------|--------|
| Gene | WDR45 (WD40 Repeat Protein 45) on Xp13 |
| Inheritance | X-linked dominant (de novo mutations in most cases) |
| Mechanism | Predominantly loss-of-function (nonsense/frameshift) |
| Allelic disorder | WARIXX (WARS2-related neurodevelopmental disorder) |
| Protein | WDR45/WIPI4 (autophagy-related beta-propeller protein) |

WDR45 encodes WIPI4, a key component of the autophagy initiation machinery. It contains six WD40 repeats forming a beta-propeller structure that mediates protein-protein interactions essential for autophagosome formation. The protein binds to the PI3KC3 (PI3-kinase class 3) complex and regulates the conversion of omegasomes into autophagosomes.

Molecular Mechanism

Autophagy Initiation Defect

WIPI4 functions in the early stages of autophagy:

Loss of WIPI4 function results in:

• 40-60% reduction in autophagosome formation rate
• Accumulation of early endosomes and multivesicular bodies
• Failure to clear damaged mitochondria (mitophagy)
• Progressive accumulation of polyubiquitinated protein aggregates

Secondary Iron Accumulation

The iron accumulation in BPAN is mechanistically distinct from PKAN and MPAN:

• Autophagic failure disrupts the normal pathway for degrading transferrin receptors
• Damaged mitochondria retain iron that would normally be recycled via mitophagy
• The resulting cellular iron dysregulation leads to deposition in the globus pallidus and substantia nigra — areas with high basal metabolic activity
• This explains why BPAN patients do not respond to pantothenate supplementation (the iron problem is downstream of an autophagy defect, not a metabolic enzyme deficiency)

Clinical Presentation

| Feature | BPAN Characteristics |
|---------|----------------------|
| Early phase | Infancy/childhood: seizures, developmental delay, intellectual disability |
| Transition | Adolescence/young adulthood: stabilization period |
| Late phase | Adulthood (typically 20s-40s): progressive neurodegeneration |
| Movement disorder | Dystonia-parkinsonism (often Levodopa-responsive parkinsonism) |
| Cognitive decline | Progressive in adulthood |
| MRI "eye of the tiger" | Present in most patients (unlike MPAN, similar to PKAN) |
| Optic atrophy | May occur |
| Seizures | Common (50-80%) |

Biphasic Disease Pattern

The biphasic pattern of BPAN distinguishes it from all other NBIA subtypes:

• Childhood phase: Static neurodevelopmental disorder (seizures, ID, motor delay)
• Adult phase: Progressive neurodegenerative movement disorder — this transition is poorly understood but represents an opportunity for disease-modifying intervention at the boundary

MRI and Diagnostic Findings

| Finding | BPAN Specifics |
|---------|----------------|
| Iron accumulation | Globus pallidus and substantia nigra |
| Eye of the tiger sign | Present in majority of patients (hypointense GP with central hyperintensity) |
| SWI hypointensity | Prominent in GP/SN |
| White matter changes | May be minimal until adult phase |
| Atrophy | Progressive caudate and brainstem atrophy in adult phase |

Therapeutic Approaches

Current Approaches

| Approach | Status | Evidence |
|----------|--------|----------|
| Anticonvulsants | Standard of care | For seizure management in childhood phase |
| Levodopa/carbidopa | Variable response | Some adults show improvement in parkinsonism |
| Physical/occupational therapy | Supportive | Maintains function across phases |
| Speech therapy | Supportive | Especially important in childhood |
| Iron chelation | Not standard | Iron is secondary consequence; primary benefit unclear |

Emerging Research

• Autophagy-enhancing compounds: Rapamycin/sirolimus (mTORC1 inhibition stimulates autophagy) — trials in BPAN
• Gene therapy: AAV-WDR45 delivery (preclinical, challenging due to X-linked requiring broad CNS coverage)
• mTOR inhibitors: Everolimus to paradoxically enhance autophagy via indirect pathway
• Early intervention: Identifying biomarkers of phase transition could enable treatment before neurodegeneration onset

Therapeutic Rationale

BPAN may be more amenable to autophagy-enhancing therapy than other NBIA subtypes because the primary defect is in autophagosome formation rather than iron metabolism. Compounds that bypass the WIPI4 requirement (e.g., via alternative autophagy pathways like LC3-associated phagocytosis) are active areas of investigation.

Cross-Links

• [NBIA Overview](/diseases/nbia)
• [PKAN Pathway](/mechanisms/pkan-neurodegeneration-pathway)
• [MPAN Pathway](/mechanisms/mitochondrial-membrane-protein-associated-neurodegeneration-mpan)
• [Autophagy-Lysosomal Pathway in Neurodegeneration](/mechanisms/autophagy-lysosomal-pathway)
• [WARS2 Gene](/genes/wars2)
• [WDR45 Gene](/genes/wdr45)

References